3-乙酰基吡咯 | 1072-82-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-乙酰基吡咯
• 中文别名: 1-(1H-吡咯-3-基)乙烷-1-酮；3-乙酰吡咯
• 英文名称: 3-acetylpyrrole
• 英文别名: 1-(1H-pyrrol-3-yl)ethan-1-one；3-acetyl-1H-pyrrole；1-(1H-pyrrol-3-yl)ethanone
• CAS: 1072-82-8
• 化学式: C₆H₇NO
• mdl: MFCD00067759
• 分子量: 109.128
• InChiKey: KHHSXHXUQVNBGA-UHFFFAOYSA-N

物化性质

• 熔点：
  115-117°C
• 沸点：
  220 C
• 密度：
  1.099±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39
• 海关编码：
  2933990090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  请将容器密封储存于阴凉干燥处。

SDS

Name:	1-(1h-pyrrol-3-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:	3-Acetylpyrrol
CAS:	1072-82-8

Section 1 - Chemical Product MSDS Name:1-(1h-pyrrol-3-yl)ethan-1-one 97% Material Safety Data Sheet
Synonym:3-Acetylpyrrol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1072-82-8	1-(1H-Pyrrol-3-yl)ethan-1-one	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1072-82-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white - brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 115 - 117 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7NO
Molecular Weight: 109

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1072-82-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(1H-Pyrrol-3-yl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1072-82-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1072-82-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1072-82-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-乙酰基吡咯是一种有机中间体，据文献报道，可用于制备IL-1抑制剂和TRPA1调节剂。

制备

3-乙酰基吡咯可由吡咯为原料制备得到。具体步骤如下：将10.0 g 吡咯添加到含有17.9 g (447.3 mmol) NaOH 的10 mL 二氯甲烷中，形成充分搅拌的悬浮液。将反应混合物冷却至0°C后，搅拌10分钟。随后，逐滴加入苯磺酰氯（31.6 g）在2 mL 二氯乙烷中的溶液。待所有试剂添加完毕后，让反应混合物恢复至室温并继续搅拌过夜。之后，向反应混合物中倒入60 mL H₂O以淬灭反应，并分离有机层。使用三倍体积的二氯甲烷（每次60 mL）萃取水相中的剩余物质。将合并后的有机萃取物用水洗涤至中性，然后用Na₂SO₄干燥。除去溶剂后，通过重结晶纯化残余物以得到3-乙酰基吡咯。

反应信息

• 作为反应物：
  描述：

  3-乙酰基吡咯 在 palladium on activated charcoal 吡啶 、 sodium azide 、 盐酸羟胺 、 氢气 、 碳酸氢钠 、 potassium carbonate 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， -78.0~60.0 ℃ 、101.33 kPa 条件下， 反应 145.0h， 生成 (S)-[[3-[3-fluoro-4-(3-acetyloximepyrrol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
  参考文献：
  名称：

  取代基对氮碳连接的（偶氮基苯基）恶唑烷酮的抗菌活性具有扩展的活性，可抵抗革兰氏阴性菌流感嗜血杆菌和卡他莫拉菌。

  摘要：

  已经制备了一系列新的氮碳连接的（偶氮基苯基）恶唑烷酮抗菌剂，以努力扩大此类抗生素的活性范围，使其包括革兰氏阴性菌。吡咯，吡唑，咪唑，三唑和四唑部分已用于取代利奈唑胺（2）的吗啉环。这些变化导致制备了对具有抵抗力的革兰氏阴性菌流感嗜血杆菌和卡他莫拉菌具有良好活性的化合物。未取代的吡咯基类似物3和1H-1,2,3-三唑基类似物6具有针对流感嗜血杆菌的MIC = 4微克/毫升，而粘膜炎莫拉氏菌= 2微克/毫升。为了在体外和体内研究其对抗菌活性的影响，还将各种取代基置于吡咯部分上。对于许多不能仅仅根据空间和唑环中氮原子的位置/数目而合理化的类似物，观察到活性上的有趣差异。活性的差异主要取决于整个唑系统电子特性的细微变化。相对于未取代的对应物，醛，醛肟和氰基唑通常可显着提高革兰氏阳性菌和革兰氏阴性菌的活性。然而，酰胺，酯，氨基，羟基，烷氧基和烷基取代基没有导致抗菌活性的改善或损失。氰基部分在唑上的放

  DOI：

  10.1021/jm990373e
• 作为产物：
  描述：

  1-(1-二乙氧基甲基-1H-吡咯-3-基)乙酮 在 sodium hydroxide 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 3-乙酰基吡咯
  参考文献：
  名称：

  Diethoxymethyl Protected Pyrroles: Synthesis and Regioselective Transformations

  摘要：

  对取代的吡咯化合物1a-k进行无水三乙基邻甲酸酯处理，可以高产率地得到二乙氧基甲基（DEM）保护衍生物2a-k。随后用三氟乙酸和乙腈以及水溶性氢氧化钠在室温下处理DEM-吡咯化合物2a-k，可以方便而温和地裂解。DEM保护适用于涉及定向邻位金属化和碘-镁交换过程的多种区域选择性转化。此外，还进行了电负性卤化反应和钯催化的偶联反应。

  DOI：

  10.1055/s-2001-18445

文献信息

• Synthesis of Natural Product-like Polyheterocycles via One-Pot Cascade Oximation, C–H Activation, and Alkyne Annulation
  作者：Liyao Zheng、Yunhui Bin、Yunpeng Wang、Ruimao Hua

  DOI：10.1021/acs.joc.6b01460

  日期：2016.10.7

  chroman-4-ones to tricyclic fused pyridines with the skeleton of cassiarins, a family of alkaloids with antimalarial activity, was developed. Also, a general strategy for modular construction of polyheterocycles with diverse natural product-like skeletons was developed by using ketone–alkyne bifunctional substrates. These reactions involved a one-pot cascade oximation of ketones, rhodium-catalyzed C–H activation

  开发了一种有效的方案，用于将苯并二氢吡喃-4-吡喃酮直接转化为具有卡西林素骨架的三环稠合吡啶，卡西林是具有抗疟疾活性的生物碱家族。另外，通过使用酮-炔双功能底物，开发了具有多种类似天然产物骨架的多杂环模块化构建的通用策略。这些反应涉及酮的一锅级联肟化，铑催化的CH活化以及在温和条件下具有高原子，阶梯和氧化还原经济性的分子间/分子内炔烃环化反应。
• [EN] 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS<br/>[FR] COMPOSES 1H-PYRAZOLE 3,4-DISUBSTITUES ET LEUR UTILISATION EN TANT QUE KINASES DEPENDANT DES CYCLINES (CDK) ET MODULATEURS DE LA GLYCOGENE SYNTHASE KINASE-3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005012256A1

  公开（公告）日：2005-02-10

  The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. Formula (0). In formula (0): X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).

  该发明提供了以下式（0）的化合物或其盐或互变异构体或N-氧化物或其溶剂合物，用于预防或治疗由细胞周期依赖性激酶和糖原合成酶-3介导的癌症等疾病状态和病症。在式（0）中：X是一个基团R1-A-NR4-或一个5-或6-成员的碳环或杂环；A是一个键，S02，C=O，NRg（C=O）或O（C=O），其中Rg是氢或C1-4烃基，可以选择性地被羟基或C1-4烷氧基取代；Y是一个键或一个由1、2或3个碳原子组成的烷基链；R1是氢；一个具有3到12个环成员的碳环或杂环基团；或一个C1-8烃基，可以选择性地被卤素（如氟）、羟基、C1-4烷氧基、氨基、单或双C1-4烃基氨基以及具有3到12个环成员的碳环或杂环基团取代，其中烃基的1或2个碳原子可以选择性地被从0、S、NH、SO、S02中选择的原子或基团所取代；R2是氢；卤素；C1-4烷氧基（如甲氧基）；或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代；R3从氢和具有3到12个环成员的碳环或杂环基团中选择；R4是氢或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代。
• [EN] NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS ARYLALCÉNYLPROPARGYLAMINE FAISANT PREUVE D'ACTION NEUROPROTECTRICE POUR LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：SEMMELWEIS EGYETEM

  公开号：WO2015087094A1

  公开（公告）日：2015-06-18

  The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

  本发明涉及一类新型的芳基烯丙炔丙胺衍生物，其具有通用公式（I）或其对应的手性异构体或对映异构体或盐，可选用药物上可接受的盐，或者这些化合物的溶剂化物。这些化合物可用于治疗或预防哺乳动物与单胺氧化酶功能障碍相关的疾病或状况，特别是在神经退行性疾病中，例如帕金森病、阿尔茨海默病或亨廷顿病。
• Synthesis of 2,2′-bipyrrole-5-carboxaldehydes and their application in the synthesis of B-ring functionalized prodiginines and tambjamines
  作者：Papireddy Kancharla、Kevin A. Reynolds

  DOI：10.1016/j.tet.2013.07.067

  日期：2013.9

  Facile, versatile, and cost-effective synthetic routes for the preparation of a range of new 3-alkyl-, 4-alkyl-, 3,4-dialkyl-, and 3-halo-4-alkyl-2,2′-bipyrrole-5-carboxaldehydes have been developed. These 2,2′-bipyrrole-5-carboxaldehydes offer interesting potential as building blocks for making bioactive natural and unnatural products, as demonstrated by the synthesis of B-ring functionalized prodiginines

  已经开发出用于制备一系列新型 3-烷基-、4-烷基-、3,4-二烷基-和 3-卤代-4-烷基-2,2′-联吡咯-5-甲醛的简单、多功能和具有成本效益的合成路线。这些 2,2′-联吡咯-5-甲醛作为制造生物活性天然和非天然产物的构建块具有有趣的潜力，正如 B 环官能化 prodiginines （PG） 和 tambjamines 的合成所证明的那样。
• [EN] BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE<br/>[FR] DERIVES DE L'IMIDAZOLE BICYCLIQUES DIRIGES CONTRE LES FLAVIVIRIDAE
  申请人：GENELABS TECH INC

  公开号：WO2005012288A1

  公开（公告）日：2005-02-10

  Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

  揭示了用于治疗黄病毒科病毒感染的化合物、组合物和方法。

表征谱图